Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
1228 participants
Study Classification
INTERVENTIONAL
Study Start Date
2007-06-30
Study Completion Date
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective of the study is to help elucidate the effects of low-dose aspirin in combination with folic acid on the incidence of live births and spontaneous abortions among a group of women who become pregnant compared to a control group.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
NCT02409680
Premature Birth
COMPLETED
NA
ASPIRIN: Neurodevelopmental Follow-up Trial
NCT04888377
Neurodevelopmental Abnormality
COMPLETED
The Effect of Low Dose Aspirin in Increasing the Chance of Pregnancy
NCT01633528
Infertility
COMPLETED
PHASE3
Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages
NCT01635426
Recurrent Pregnancy Loss
UNKNOWN
PHASE2/PHASE3
Low Molecular Weight Heparin and/or Aspirin in Prevention of Habitual Abortion
NCT00959621
Habitual Abortion
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Despite the fundamental nature of reproduction, for many it is a process fraught with frustration, inefficiency and imperfections, the effects of which can be severe. Infertility affects 10-15% of couples attempting to conceive. Among all women who conceive, the incidence of spontaneous abortion (SA) has been estimated to be between 15 and 31%, and in many cases the cause is unknown. Additionally, of the four million births yearly in the United States, between 8 and 15% will be born prematurely and experience increased morbidity and mortality as a result. An intervention with even a small absolute effect on any of these outcomes has great implications at the population level due to the large potential attributable benefit.
One such potential intervention is low-dose acetylsalicylic-acid (aspirin). Aspirin has been a primary target of interest because of its anti-inflammatory, vasodilatory and platelet aggregation inhibition properties. To evaluate the effects of low-dose aspirin in combination with folic acid on the incidence of live births and spontaneous abortion, we are conducting a multi-site randomized controlled trial study with two sites and one data coordinating center. Women aged 18-40 currently trying to become pregnant and who have had a single spontaneous abortion in the past year will be eligible for the study. The recruitment goal is 1600 women. Participating women will be randomly assigned to one of two treatment groups. Those randomized to treatment will receive daily low-dose aspirin. Those randomized to placebo will receive daily placebo. Both groups will receive folic acid daily in accordance with recommendations from the U.S. Public Health Service for prevention of birth defects. The duration of treatment regimens (LDA and folic acid or placebo and folic acid) will be 6 menstrual cycles, with those who become pregnant continuing until the end of pregnancy. Monthly urine and blood samples will be collected and questionnaires administered.
One such potential intervention is low-dose acetylsalicylic-acid (aspirin). Aspirin has been a primary target of interest because of its anti-inflammatory, vasodilatory and platelet aggregation inhibition properties. To evaluate the effects of low-dose aspirin in combination with folic acid on the incidence of live births and spontaneous abortion, we are conducting a multi-site randomized controlled trial study with two sites and one data coordinating center. Women aged 18-40 currently trying to become pregnant and who have had a single spontaneous abortion in the past year will be eligible for the study. The recruitment goal is 1600 women. Participating women will be randomly assigned to one of two treatment groups. Those randomized to treatment will receive daily low-dose aspirin. Those randomized to placebo will receive daily placebo. Both groups will receive folic acid daily in accordance with recommendations from the U.S. Public Health Service for prevention of birth defects. The duration of treatment regimens (LDA and folic acid or placebo and folic acid) will be 6 menstrual cycles, with those who become pregnant continuing until the end of pregnancy. Monthly urine and blood samples will be collected and questionnaires administered.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Birth
Spontaneous Abortion
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aspirin
81mg of low-dose aspirin plus 400micrograms of folic acid.
Group Type
ACTIVE_COMPARATOR
acetylsalicylic-acid (aspirin)
Intervention Type
DRUG
81mg of low-dose aspirin plus 400micrograms of folic acid.
Placebo
400micrograms of folic acid.
Group Type
PLACEBO_COMPARATOR
Folic acid
Intervention Type
DIETARY_SUPPLEMENT
400micrograms of folic acid.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
acetylsalicylic-acid (aspirin)
81mg of low-dose aspirin plus 400micrograms of folic acid.
Intervention Type
DRUG
Folic acid
400micrograms of folic acid.
Intervention Type
DIETARY_SUPPLEMENT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
aspirin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women experiencing one or two pregnancy losses at any point in gestation in the past that were not elective termination(s). At least one of these losses must be well documented by one of the following:
* Sonogram demonstrating anembryonic loss, embryonic loss or fetal death.
* Histologic confirmation of products of conception that were spontaneously passed per vagina or surgically obtained.
* Hospital records of fetus delivery.
* Late menses and positive serum hCG or positive urine hCG documented by hospital or clinic records followed by either a negative hospital/clinic pregnancy test or a decline in urinary hCG level over 3 days.
* Home pregnancy tests without hCG confirmation from a healthcare provider (either serum or urine) will not be accepted.
* No more than 5 pregnancies in total including the pregnancy loss(es).\*
* Up to two prior pregnancies that did not end in a loss.\*
\*Women may have up to two pregnancies beyond 20 weeks that were not losses, two spontaneous pregnancy losses at any time in the past, and up to one therapeutic or elective termination (two therapeutic or elective terminations if no other pregnancies). Ectopic and molar pregnancies would, for the purpose of enrollment, be considered in the same category as therapeutic termination pregnancies. Women with more than two live births or those with more than two losses, regardless of the week of gestation of the loss, are excluded.
* Presence of intact tubes (both), ovaries (both), and uterus.
* Between 18 and 40 years of age at time of baseline visit.
* Regular menstrual periods between 21 - 42 days in length (within the last 12 months). Regular menstrual periods are defined as no more than an 8-day difference between the woman's shortest and longest cycle.
* No more than one missed menses in the past 12 months (other than those missed due to pregnancy or breastfeeding).
* Actively trying to conceive with a male partner and not using contraception by the baseline visit.
* Not currently pregnant at the baseline or randomization visits.
* Ability and willingness to give informed consent.
* Willingness to be randomized and to take daily study pills for 6 months to a possible 15 months
Exclusions Criteria:
* Known allergies to aspirin or non-steroidal anti-inflammatory agents.
* Clinical indication for anticoagulant therapy. These include prior or current thrombosis, antiphospholipid syndrome (APS) or known major thrombophilia.
* Clinical indication for chronic use of NSAIDs such as rheumatoid arthritis.
* Indication for additional folic acid supplementation, such as prior infant with neural tube defect (NTD), seizure disorder.
* Medical contraindication to aspirin therapy. These include uncontrolled asthma, nasal polyps, bleeding disorders, or history of gastrointestinal ulcer.
* Sonogram demonstrating anembryonic loss, embryonic loss or fetal death.
* Histologic confirmation of products of conception that were spontaneously passed per vagina or surgically obtained.
* Hospital records of fetus delivery.
* Late menses and positive serum hCG or positive urine hCG documented by hospital or clinic records followed by either a negative hospital/clinic pregnancy test or a decline in urinary hCG level over 3 days.
* Home pregnancy tests without hCG confirmation from a healthcare provider (either serum or urine) will not be accepted.
* No more than 5 pregnancies in total including the pregnancy loss(es).\*
* Up to two prior pregnancies that did not end in a loss.\*
\*Women may have up to two pregnancies beyond 20 weeks that were not losses, two spontaneous pregnancy losses at any time in the past, and up to one therapeutic or elective termination (two therapeutic or elective terminations if no other pregnancies). Ectopic and molar pregnancies would, for the purpose of enrollment, be considered in the same category as therapeutic termination pregnancies. Women with more than two live births or those with more than two losses, regardless of the week of gestation of the loss, are excluded.
* Presence of intact tubes (both), ovaries (both), and uterus.
* Between 18 and 40 years of age at time of baseline visit.
* Regular menstrual periods between 21 - 42 days in length (within the last 12 months). Regular menstrual periods are defined as no more than an 8-day difference between the woman's shortest and longest cycle.
* No more than one missed menses in the past 12 months (other than those missed due to pregnancy or breastfeeding).
* Actively trying to conceive with a male partner and not using contraception by the baseline visit.
* Not currently pregnant at the baseline or randomization visits.
* Ability and willingness to give informed consent.
* Willingness to be randomized and to take daily study pills for 6 months to a possible 15 months
Exclusions Criteria:
* Known allergies to aspirin or non-steroidal anti-inflammatory agents.
* Clinical indication for anticoagulant therapy. These include prior or current thrombosis, antiphospholipid syndrome (APS) or known major thrombophilia.
* Clinical indication for chronic use of NSAIDs such as rheumatoid arthritis.
* Indication for additional folic acid supplementation, such as prior infant with neural tube defect (NTD), seizure disorder.
* Medical contraindication to aspirin therapy. These include uncontrolled asthma, nasal polyps, bleeding disorders, or history of gastrointestinal ulcer.
Exclusion Criteria
* Currently undergoing/planned use of assisted reproductive techniques during trial (IVF; IUI; Clomid).
* History of infertility or sub-fertility. This includes any of the following:
* No conception after ≥ 1 year of unprotected intercourse and actively trying to conceive.
* Any prior medical treatment for infertility.
* Prior treatment for known pelvic inflammatory disease.
* Known male infertility or sperm abnormality (current partner).
* Known tubal occlusion, anovulation, uterine abnormality, or endometriosis stage III or IV.
* History of polycystic ovarian syndrome.
* Presence of unstable mental disorder. These include bipolar illness, schizophrenia, uncontrolled depression, uncontrolled anxiety disorder.
* Known current or recent alcohol abuse or illicit drug use.
* Current diagnosis of sexually transmitted infection (STI) (temporary exclusion)
* History of infertility or sub-fertility. This includes any of the following:
* No conception after ≥ 1 year of unprotected intercourse and actively trying to conceive.
* Any prior medical treatment for infertility.
* Prior treatment for known pelvic inflammatory disease.
* Known male infertility or sperm abnormality (current partner).
* Known tubal occlusion, anovulation, uterine abnormality, or endometriosis stage III or IV.
* History of polycystic ovarian syndrome.
* Presence of unstable mental disorder. These include bipolar illness, schizophrenia, uncontrolled depression, uncontrolled anxiety disorder.
* Known current or recent alcohol abuse or illicit drug use.
* Current diagnosis of sexually transmitted infection (STI) (temporary exclusion)
Minimum Eligible Age
18 Years
Maximum Eligible Age
40 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Enrique Schisterman
Chief and Senior Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Enrique F Schisterman, PhD
Role: PRINCIPAL_INVESTIGATOR
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Jean Wactawski-Wende, PhD
Role: PRINCIPAL_INVESTIGATOR
University at Buffalo
Robert Silver, MD
Role: PRINCIPAL_INVESTIGATOR
University of Utah
Noya Galai, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Haifa
Janet Townsend, M.D.
Role: PRINCIPAL_INVESTIGATOR
The Commonwealth Medical College
Anne Lynch, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Colorado, Denver
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado, Denver School of Medicine, Department of Obstetrics and Gynecology
Denver, Colorado, United States
Site Status
Women's Health Research Center, Department of Social and Preventive Medicine, University at Buffalo
Buffalo, New York, United States
Site Status
Moses Taylor Hospital
Scranton, Pennsylvania, United States
Site Status
University of Utah Medical Center
Salt Lake City, Utah, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Lee IT, Barnhart KT, Hwang WT, Hinkle SN, Johnstone E, Mills JL, Caniglia EC, Schisterman EF, Mendola P, Ryan GL, Hotaling J, Peterson CM, Van Voorhis BJ, Mumford SL. Association between markers of female adiposity and live birth among patients undergoing fertility treatment or attempting unassisted conception. Hum Reprod. 2025 Sep 1;40(9):1671-1680. doi: 10.1093/humrep/deaf124.
Reference Type
DERIVED
Freeman JR, Whitcomb BW, Bertone-Johnson ER, O'Brien LM, Dunietz GL, Purdue-Smithe AC, Kim K, Silver RM, Schisterman EF, Mumford SL. Preconception sleep, pregnancy loss, and adverse pregnancy outcomes among women with a history of pregnancy loss. Hum Reprod. 2025 Jul 1;40(7):1366-1376. doi: 10.1093/humrep/deaf074.
Reference Type
DERIVED
Freeman JR, Whitcomb BW, Bertone-Johnson ER, O'Brien LM, Dunietz GL, Purdue-Smithe AC, Kim K, Silver RM, Schisterman EF, Mumford SL. Sleep characteristics in association with risk of sporadic anovulation among eumenorrheic women. Chronobiol Int. 2025 Apr;42(4):500-510. doi: 10.1080/07420528.2025.2481165. Epub 2025 Mar 31.
Reference Type
DERIVED
Nobles CJ, Mendola P, Kim K, Pollack AZ, Mumford SL, Perkins NJ, Silver RM, Schisterman EF. Preconception Phthalate Exposure and Women's Reproductive Health: Pregnancy, Pregnancy Loss, and Underlying Mechanisms. Environ Health Perspect. 2023 Dec;131(12):127013. doi: 10.1289/EHP12287. Epub 2023 Dec 13.
Reference Type
DERIVED
Nobles CJ, Mendola P, Mumford SL, Silver RM, Kim K, Perkins NJ, Schisterman EF. The Relationship of Preconception and Early Pregnancy Isoprostanes with Fecundability and Pregnancy Loss. Epidemiology. 2023 Sep 1;34(5):759-766. doi: 10.1097/EDE.0000000000001631. Epub 2023 Jul 31.
Reference Type
DERIVED
Freeman JR, Whitcomb BW, Bertone-Johnson ER, Balzer LB, O'Brien LM, Dunietz GL, Purdue-Smithe AC, Kim K, Silver RM, Schisterman EF, Mumford SL. Preconception sleep duration, sleep timing, and shift work in association with fecundability and live birth among women with a history of pregnancy loss. Fertil Steril. 2023 Feb;119(2):252-263. doi: 10.1016/j.fertnstert.2022.10.026. Epub 2022 Dec 29.
Reference Type
DERIVED
Schliep KC, Hinkle SN, Kim K, Sjaarda LA, Silver RM, Stanford JB, Purdue-Smithe A, Plowden TC, Schisterman EF, Mumford SL. Prospectively assessed perceived stress associated with early pregnancy losses among women with history of pregnancy loss. Hum Reprod. 2022 Sep 30;37(10):2264-2274. doi: 10.1093/humrep/deac172.
Reference Type
DERIVED
Zolton JR, Sjaarda LA, Mumford SL, Holland TL, Kim K, Flannagan KS, Yisahak SF, Hinkle SN, Connell MT, White MV, Perkins NJ, Silver RM, Hill MJ, DeCherney AH, Schisterman EF. Preconception hemoglobin A1c concentration in healthy women is not associated with fecundability or pregnancy loss. F S Rep. 2022 Jan 20;3(1):39-46. doi: 10.1016/j.xfre.2022.01.002. eCollection 2022 Mar.
Reference Type
DERIVED
Zhong Y, Brooks MM, Kennedy EH, Bodnar LM, Naimi AI. Use of Machine Learning to Estimate the Per-Protocol Effect of Low-Dose Aspirin on Pregnancy Outcomes: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2022 Mar 1;5(3):e2143414. doi: 10.1001/jamanetworkopen.2021.43414.
Reference Type
DERIVED
Purdue-Smithe AC, Kim K, Schliep KC, DeVilbiss EA, Hinkle SN, Ye A, Perkins NJ, Sjaarda LA, Silver RM, Schisterman EF, Mumford SL. Preconception caffeine metabolites, caffeinated beverage intake, and fecundability. Am J Clin Nutr. 2022 Apr 1;115(4):1227-1236. doi: 10.1093/ajcn/nqab435.
Reference Type
DERIVED
Purdue-Smithe AC, Kim K, Andriessen VC, Pollack AZ, Sjaarda LA, Silver RM, Schisterman EF, Mumford SL. Preconception leukocyte telomere length and pregnancy outcomes among women with demonstrated fecundity. Hum Reprod. 2021 Nov 18;36(12):3122-3130. doi: 10.1093/humrep/deab201.
Reference Type
DERIVED
Alkhalaf Z, Kim K, Kuhr DL, Radoc JG, Purdue-Smithe A, Pollack AZ, Yisahak SF, Silver RM, Thoma M, Kissell K, Perkins NJ, Sjaarda LA, Mumford SL. Markers of vitamin D metabolism and premenstrual symptoms in healthy women with regular cycles. Hum Reprod. 2021 Jun 18;36(7):1808-1820. doi: 10.1093/humrep/deab089.
Reference Type
DERIVED
Naimi AI, Perkins NJ, Sjaarda LA, Mumford SL, Platt RW, Silver RM, Schisterman EF. The Effect of Preconception-Initiated Low-Dose Aspirin on Human Chorionic Gonadotropin-Detected Pregnancy, Pregnancy Loss, and Live Birth : Per Protocol Analysis of a Randomized Trial. Ann Intern Med. 2021 May;174(5):595-601. doi: 10.7326/M20-0469. Epub 2021 Jan 26.
Reference Type
DERIVED
Mumford SL, Flannagan KS, Radoc JG, Sjaarda LA, Zolton JR, Metz TD, Plowden TC, Perkins NJ, DeVilbiss EA, Andriessen VC, A C PS, Kim K, Yisahak SF, Freeman JR, Alkhalaf Z, Silver RM, Schisterman EF. Cannabis use while trying to conceive: a prospective cohort study evaluating associations with fecundability, live birth and pregnancy loss. Hum Reprod. 2021 Apr 20;36(5):1405-1415. doi: 10.1093/humrep/deaa355.
Reference Type
DERIVED
Flannagan KS, Mumford SL, Sjaarda LA, Radoc JG, Perkins NJ, Andriessen VC, Zolton JR, Silver RM, Schisterman EF. Is opioid use safe in women trying to conceive? Epidemiology. 2020 Nov;31(6):844-851. doi: 10.1097/EDE.0000000000001247.
Reference Type
DERIVED
Sjaarda LA, Radoc JG, Flannagan KS, Mumford SL, Kim K, Perkins NJ, Silver RM, Schisterman EF. Urinary selective serotonin reuptake inhibitors across critical windows of pregnancy establishment: a prospective cohort study of fecundability and pregnancy loss. Fertil Steril. 2020 Dec;114(6):1278-1287. doi: 10.1016/j.fertnstert.2020.06.037. Epub 2020 Oct 14.
Reference Type
DERIVED
Evans MB, Nobles CJ, Kim K, Hill MJ, DeCherney AH, Silver RM, Mumford SL, Sjaarda LA, Perkins NJ, Schisterman EF. Low-dose aspirin in reproductive health: effects on menstrual cycle characteristics. Fertil Steril. 2020 Dec;114(6):1263-1270. doi: 10.1016/j.fertnstert.2020.06.022. Epub 2020 Sep 4.
Reference Type
DERIVED
Nobles CJ, Mendola P, Mumford SL, Silver RM, Kim K, Andriessen VC, Connell M, Sjaarda L, Perkins NJ, Schisterman EF. Preconception Blood Pressure and Its Change Into Early Pregnancy: Early Risk Factors for Preeclampsia and Gestational Hypertension. Hypertension. 2020 Sep;76(3):922-929. doi: 10.1161/HYPERTENSIONAHA.120.14875. Epub 2020 Aug 3.
Reference Type
DERIVED
Hamulyak EN, Scheres LJ, Marijnen MC, Goddijn M, Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev. 2020 May 2;5(5):CD012852. doi: 10.1002/14651858.CD012852.pub2.
Reference Type
DERIVED
Yeung EH, Guan W, Zeng X, Salas LA, Mumford SL, de Prado Bert P, van Meel ER, Malmberg A, Sunyer J, Duijts L, Felix JF, Czamara D, Hamalainen E, Binder EB, Raikkonen K, Lahti J, London SJ, Silver RM, Schisterman EF. Cord blood DNA methylation reflects cord blood C-reactive protein levels but not maternal levels: a longitudinal study and meta-analysis. Clin Epigenetics. 2020 Apr 30;12(1):60. doi: 10.1186/s13148-020-00852-2.
Reference Type
DERIVED
Russo LM, Whitcomb BW, Freeman JR, Mumford SL, Sjaarda LA, Perkins NJ, Schliep KC, Grewal J, Silver RM, Schisterman EF. Physical activity and incidence of subclinical and clinical pregnancy loss: a secondary analysis in the effects of aspirin in gestation and reproduction randomized trial. Fertil Steril. 2020 Mar;113(3):601-608.e1. doi: 10.1016/j.fertnstert.2019.10.027.
Reference Type
DERIVED
Robinson SL, Mumford SL, Guan W, Zeng X, Kim K, Radoc JG, Trinh MH, Flannagan K, Schisterman EF, Yeung E. Maternal fatty acid concentrations and newborn DNA methylation. Am J Clin Nutr. 2020 Mar 1;111(3):613-621. doi: 10.1093/ajcn/nqz311.
Reference Type
DERIVED
Agrawala S, Sjaarda LA, Omosigho UR, Perkins NJ, Silver RM, Mumford SL, Connell MT, Naimi AI, Halvorson LM, Schisterman EF. Effect of preconception low dose aspirin on pregnancy and live birth according to socioeconomic status: A secondary analysis of a randomized clinical trial. PLoS One. 2019 Apr 18;14(4):e0200533. doi: 10.1371/journal.pone.0200533. eCollection 2019.
Reference Type
DERIVED
Mumford SL, Browne RW, Kim K, Nichols C, Wilcox B, Silver RM, Connell MT, Holland TL, Kuhr DL, Omosigho UR, Perkins NJ, Radin R, Sjaarda LA, Schisterman EF. Preconception Plasma Phospholipid Fatty Acids and Fecundability. J Clin Endocrinol Metab. 2018 Dec 1;103(12):4501-4510. doi: 10.1210/jc.2018-00448.
Reference Type
DERIVED
Mumford SL, Garbose RA, Kim K, Kissell K, Kuhr DL, Omosigho UR, Perkins NJ, Galai N, Silver RM, Sjaarda LA, Plowden TC, Schisterman EF. Association of preconception serum 25-hydroxyvitamin D concentrations with livebirth and pregnancy loss: a prospective cohort study. Lancet Diabetes Endocrinol. 2018 Sep;6(9):725-732. doi: 10.1016/S2213-8587(18)30153-0. Epub 2018 May 31.
Reference Type
DERIVED
Gibbins KJ, Mumford SL, Sjaarda LA, Branch DW, Perkins NJ, Ye A, Schisterman EF, Silver RM. Preconception antiphospholipid antibodies and risk of subsequent early pregnancy loss. Lupus. 2018 Aug;27(9):1437-1445. doi: 10.1177/0961203318776089. Epub 2018 May 17.
Reference Type
DERIVED
Russo LM, Whitcomb BW, Mumford SL, Hawkins M, Radin RG, Schliep KC, Silver RM, Perkins NJ, Kim K, Omosigho UR, Kuhr DL, Holland TL, Sjaarda LA, Schisterman EF. A prospective study of physical activity and fecundability in women with a history of pregnancy loss. Hum Reprod. 2018 Jul 1;33(7):1291-1298. doi: 10.1093/humrep/dey086.
Reference Type
DERIVED
Nobles CJ, Mendola P, Mumford SL, Naimi AI, Yeung EH, Kim K, Park H, Wilcox B, Silver RM, Perkins NJ, Sjaarda L, Schisterman EF. Preconception Blood Pressure Levels and Reproductive Outcomes in a Prospective Cohort of Women Attempting Pregnancy. Hypertension. 2018 May;71(5):904-910. doi: 10.1161/HYPERTENSIONAHA.117.10705. Epub 2018 Apr 2.
Reference Type
DERIVED
Kuhr DL, Sjaarda LA, Alkhalaf Z, Omosigho UR, Connell MT, Silver RM, Kim K, Perkins NJ, Holland TL, Plowden TC, Schisterman EF, Mumford SL. Vitamin D is associated with bioavailability of androgens in eumenorrheic women with prior pregnancy loss. Am J Obstet Gynecol. 2018 Jun;218(6):608.e1-608.e6. doi: 10.1016/j.ajog.2018.03.012. Epub 2018 Mar 13.
Reference Type
DERIVED
Sjaarda LA, Mumford SL, Kuhr DL, Holland TL, Silver RM, Plowden TC, Perkins NJ, Schisterman EF. Association of testosterone and antimullerian hormone with time to pregnancy and pregnancy loss in fecund women attempting pregnancy. Fertil Steril. 2018 Mar;109(3):540-548.e1. doi: 10.1016/j.fertnstert.2017.11.014. Epub 2018 Feb 7.
Reference Type
DERIVED
Radin RG, Sjaarda LA, Silver RM, Nobles CJ, Mumford SL, Perkins NJ, Wilcox BD, Pollack AZ, Schliep KC, Plowden TC, Schisterman EF. C-Reactive protein in relation to fecundability and anovulation among eumenorrheic women. Fertil Steril. 2018 Feb;109(2):232-239.e1. doi: 10.1016/j.fertnstert.2017.10.025. Epub 2018 Jan 6.
Reference Type
DERIVED
Plowden TC, Schisterman EF, Sjaarda LA, Perkins NJ, Silver R, Radin R, Kim K, Galai N, DeCherney AH, Mumford SL. Thyroid-stimulating hormone, anti-thyroid antibodies, and pregnancy outcomes. Am J Obstet Gynecol. 2017 Dec;217(6):697.e1-697.e7. doi: 10.1016/j.ajog.2017.09.001. Epub 2017 Sep 14.
Reference Type
DERIVED
Pugh SJ, Schisterman EF, Browne RW, Lynch AM, Mumford SL, Perkins NJ, Silver R, Sjaarda L, Stanford JB, Wactawski-Wende J, Wilcox B, Grantz KL. Preconception maternal lipoprotein levels in relation to fecundability. Hum Reprod. 2017 May 1;32(5):1055-1063. doi: 10.1093/humrep/dex052.
Reference Type
DERIVED
Sjaarda LA, Radin RG, Silver RM, Mitchell E, Mumford SL, Wilcox B, Galai N, Perkins NJ, Wactawski-Wende J, Stanford JB, Schisterman EF. Preconception Low-Dose Aspirin Restores Diminished Pregnancy and Live Birth Rates in Women With Low-Grade Inflammation: A Secondary Analysis of a Randomized Trial. J Clin Endocrinol Metab. 2017 May 1;102(5):1495-1504. doi: 10.1210/jc.2016-2917.
Reference Type
DERIVED
Radin RG, Sjaarda LA, Perkins NJ, Silver RM, Chen Z, Lesher LL, Galai N, Wactawski-Wende J, Mumford SL, Schisterman EF. Low-Dose Aspirin and Sporadic Anovulation in the EAGeR Randomized Trial. J Clin Endocrinol Metab. 2017 Jan 1;102(1):86-92. doi: 10.1210/jc.2016-2095.
Reference Type
DERIVED
Hinkle SN, Mumford SL, Grantz KL, Silver RM, Mitchell EM, Sjaarda LA, Radin RG, Perkins NJ, Galai N, Schisterman EF. Association of Nausea and Vomiting During Pregnancy With Pregnancy Loss: A Secondary Analysis of a Randomized Clinical Trial. JAMA Intern Med. 2016 Nov 1;176(11):1621-1627. doi: 10.1001/jamainternmed.2016.5641.
Reference Type
DERIVED
Zarek SM, Mitchell EM, Sjaarda LA, Mumford SL, Silver RM, Stanford JB, Galai N, Schliep KC, Radin RG, Plowden TC, DeCherney AH, Schisterman EF. Antimullerian hormone and pregnancy loss from the Effects of Aspirin in Gestation and Reproduction trial. Fertil Steril. 2016 Apr;105(4):946-952.e2. doi: 10.1016/j.fertnstert.2015.12.003. Epub 2015 Dec 17.
Reference Type
DERIVED
Zarek SM, Mitchell EM, Sjaarda LA, Mumford SL, Silver RM, Stanford JB, Galai N, White MV, Schliep KC, DeCherney AH, Schisterman EF. Is Anti-Mullerian Hormone Associated With Fecundability? Findings From the EAGeR Trial. J Clin Endocrinol Metab. 2015 Nov;100(11):4215-21. doi: 10.1210/jc.2015-2474. Epub 2015 Sep 25.
Reference Type
DERIVED
Radin RG, Mumford SL, Silver RM, Lesher LL, Galai N, Faraggi D, Wactawski-Wende J, Townsend JM, Lynch AM, Simhan HN, Sjaarda LA, Perkins NJ, Zarek SM, Schliep KC, Schisterman EF. Sex ratio following preconception low-dose aspirin in women with prior pregnancy loss. J Clin Invest. 2015 Sep;125(9):3619-26. doi: 10.1172/JCI82357. Epub 2015 Aug 17.
Reference Type
DERIVED
Silver RM, Ahrens K, Wong LF, Perkins NJ, Galai N, Lesher LL, Faraggi D, Wactawski-Wende J, Townsend JM, Lynch AM, Mumford SL, Sjaarda L, Schisterman EF. Low-dose aspirin and preterm birth: a randomized controlled trial. Obstet Gynecol. 2015 Apr;125(4):876-884. doi: 10.1097/AOG.0000000000000736.
Reference Type
DERIVED
Schisterman EF, Mumford SL, Schliep KC, Sjaarda LA, Stanford JB, Lesher LL, Wactawski-Wende J, Lynch AM, Townsend JM, Perkins NJ, Zarek SM, Tsai MY, Chen Z, Faraggi D, Galai N, Silver RM. Preconception low dose aspirin and time to pregnancy: findings from the effects of aspirin in gestation and reproduction randomized trial. J Clin Endocrinol Metab. 2015 May;100(5):1785-91. doi: 10.1210/jc.2014-4179. Epub 2015 Feb 24.
Reference Type
DERIVED
Schisterman EF, Silver RM, Lesher LL, Faraggi D, Wactawski-Wende J, Townsend JM, Lynch AM, Perkins NJ, Mumford SL, Galai N. Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial. Lancet. 2014 Jul 5;384(9937):29-36. doi: 10.1016/S0140-6736(14)60157-4. Epub 2014 Apr 2.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
https://www.nichd.nih.gov/about/org/diphr/eb/research/pages/effects-aspirin.aspx
EAGeR Trial Home Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EAGeR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting
NCT01276691
COMPLETED
PHASE4
Lovenox With Aspirin in Thawed Blastocyst Transfer
NCT06133803
RECRUITING
PHASE4
Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT
NCT00564174
TERMINATED
NA
The Effects of Aspirin and Acetaminophen on the Stomach in Healthy Volunteers
NCT00594867
COMPLETED
PHASE4
Testing a Community Intervention to Increase Aspirin Use
NCT02607917
COMPLETED
NA
Effectiveness of Aspirin in Compare With Heparin Plus Aspirin in Recurrent Pregnancy Loss Treatment
NCT01542411
COMPLETED
Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients
NCT02966002
TERMINATED
PHASE4
IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes
NCT03574909
UNKNOWN
PHASE3
The Effect of Low Dose Aspirin on the Pharmacokinetics of Methotrexate
NCT00464997
UNKNOWN
Effect of Aspirin on Gut Microbiome
NCT02761486
COMPLETED
PHASE1
Mechanism Based Resistance to Aspirin
NCT00948987
COMPLETED
PHASE1
The Effect of a Probiotic Strain on Aspirin-induced GI Damage.
NCT03228589
COMPLETED
PHASE2
Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin
NCT01081353
COMPLETED
PHASE1
Aspirin Statins Or Both For The Reduction Of Thrombin Generation In Diabetic People
NCT00793754
COMPLETED
PHASE4
Pharmacokinetic and Pharmacodynamic Study of a Novel Sublingual Aspirin Tablet
NCT04792723
UNKNOWN
PHASE1
Aspirin in Reducing Events in the Elderly
NCT01038583
UNKNOWN
Prospective Double-blind Study for the Use of Aspirin During Transurethral Surgery of the Bladder or the Prostate
NCT00861367
WITHDRAWN
NA
ASPirin Intervention for the REDuction of Colorectal Cancer Risk
NCT02394769
ACTIVE_NOT_RECRUITING
NA
Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation
NCT01616615
COMPLETED
PHASE2
Dose-related Effect of Aspirin on Laboratory-defined Acetylsalicylic Acid Resistance and Clinical Outcome After Coronary Stenting
NCT00966485
COMPLETED
NA
Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?
NCT00578760
UNKNOWN
NA
Aspirin in Patients With Myocardial Infarction and Thrombocytopenia
NCT00501345
TERMINATED
PHASE3
Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy
NCT07086183
NOT_YET_RECRUITING
An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants
NCT03341390
COMPLETED
PHASE1
Unruptured Intracranial Aneurysm Aspirin Trial (UIAAT).
NCT03661463
UNKNOWN
PHASE2